New Zealand markets open in 5 hours 40 minutes

Pfizer Inc. (PFE)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
50.91-0.17 (-0.33%)
At close: 04:03PM EST
50.63 -0.28 (-0.55%)
After hours: 07:57PM EST
Full screen
Trade prices are not sourced from all markets
Previous close51.08
Open50.56
Bid50.63 x 800
Ask50.91 x 4000
Day's range50.48 - 51.32
52-week range41.45 - 61.71
Volume16,881,642
Avg. volume20,140,077
Market cap285.774B
Beta (5Y monthly)0.64
PE ratio (TTM)9.62
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.60 (3.23%)
Ex-dividend date03 Nov 2022
1y target estN/A
  • Business Wire

    Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day

    NEW YORK, December 01, 2022--Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live video webcast of its Near-Term Launches + High-Value Pipeline Day on Monday, December 12, 2022 from 1:00 p.m. EST to 6:00 p.m. EST, with an approximately 30 minute break at the midpoint. Pfizer business executives and scientific leadership will provide updates on the company’s potential near-term product launches and key high-value pipeline programs, both of which are expected to be pri

  • GlobeNewswire

    Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases

    Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody that blocks tumor necrosis factor-like ligand 1A (TL1A), a cytokine believed to play a key role in inflammation and fibrosis RVT-3101 is currently being evaluated in a large global Phase 2b study (TUSCANY-2) with final results expected in 1H 2023 BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) and Pfizer Inc. (NYSE: PF

  • Business Wire

    Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

    NEW YORK, November 28, 2022--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceuticals Business; Kevin Sullivan, Global Specialty Care & U.S. President; and Navin Katyal, U.S. Commercial and Global Business Lead for mRNA Portfolio, at the Evercore ISI HealthCONx Conference on Thursday, December 1, 2022 at 4:20 p.m. EST.